Page 247 - Aet News Today

FDA approval of Tecvayli, from Johnson & Johnson subsidiary Janssen Biotech, makes it the newest therapy that treats multiple myeloma by targeting the cancer protein BCMA. Though this off-the-shelf drug offers patients a more convenient dosing option, it comes with similar complication risks as other biologics approved for this type of blood cancer.

Patient privacy is a winner of the transition to GA4. Making the switch to the new analytics platform will allow your organization to more easily adhere to HIPAA regulations, working with other patient privacy standards to keep patient data safe and secure.

The industry faces challenges from inflation to labor shortages, according to an annual report from EY. However, there are grounds for optimism and areas to focus on, such as patching up supply chains.

Realizing the value of cloud, life sciences companies and leading pharma organizations across the world's R&D teams are increasing operations to collaborate and drive clinical trials.

AstraZeneca drug Imjudo is now FDA approved for treating advanced liver cancer. The infused therapy is administered under a novel dosing schedule in addition to Imfinzi, an AstraZeneca drug already approved for treating several different types of cancer.

In order to engage more Americans in primary care, we need to understand the main challenges that surround primary care in the U.S., according to Dr. Stephen Ezeji-Okoye, Crossover Health’s chief medical officer. Some of these include the increasing shortage of primary care physicians and the lack of incentivization to focus on whole-person health and preventive care.

In an opinion published Friday by Ninth Circuit Judge Ronald Gould said, “Invoking journalism and the First Amendment does not shield individuals from liability for violations of laws applicable to all members of society.”

Join us in this webinar presented by flipMD and learn how to remain at the forefront of healthcare and adapt to patients’ needs, business leader, and leverage physician insights.

Many of rural America’s health problems can be traced back to access to care. Rural Americans face environmental and economic access biases that are very different from their urban and suburban counterparts.

Through apps, pharmaceutical companies can actually influence patient adherence and mindset after that patient has been prescribed that company's medication by their physician.